Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We did have a mention in the pre show article previously noted here but not in the undernoted article from 18 Dec
https://www.wholefoodsmagazine.com/articles/16581-10-macro-trends-from-supplyside-west-2023
A number of names you will recognise and a number of areas where we could have got a mention but didn't
mol
DSM-Firmenich 311023 qtr report extract
The integration of the merged TTH businesses has shown good signs of traction in the areas of cross-selling and the development of new joint concepts. As an example of the latter, a new flavored immunity-supporting dairy drink was launched, combining both taste (strawberry and banana flavor) and ingredients solutions. Other examples of early synergies are for instance in sugar reduction, one of the cornerstone growth platforms of TTH.
https://www.dsm-firmenich.com/corporate/news/press-releases/2023/dsm-firmenich-reports-q3-2023-results.html
mind at our current mc of c23m plus say a premium of even 23m
this enlarged group could make an offer for not only our sweetbiotix but everyhing else and hardly break sweat at the price - this option has of course also existed previously for other prospective suitors and partners but no offers ever made
we are but a very tiny player in this vast market and whilst we have been linked/signed/collaborated in numerous deals since listing our turnover and profitability (lets be honest losses) are unfortunately laughable
still prepared to give 2024 a go though
mol
From 01 Nov 23 rns
The Company's focus for 2023 has been on achieving profitability on a per business unit basis and, once achieved ultimately resulting in overall profitability. This is being driven by a reduction in costs, a focus on existing partners returning to forecast, bringing in new partners particularly in the USA and Asia, and building an e-commerce business through multiple channels to reduce partner dependency. This update seeks to capture the progress made with first generation products since the restructuring of the management team in March in each of these areas.
An update on second generation products will be provided separately in due course.
I have separated the last line from paragraph as released in rns - certainly didn't suggest to me that it would be before Dec 23 nor unfortunately early 2024 - we will see
Prior to that we had 27 Sep 23 half year report
i've edited to sweetbiotix reference only - which basically is the usual opti speak
We are particularly excited about our second-generation products approaching commercialisation given their uniqueness in the marketplace. Our sweet prebiotic fibres, called SweetBiotix® create the opportunity to replace unhealthy calorific and cariogenic sugars with healthy fibres in a wide range of food and beverage products. With growing health concerns over traditional sugars and sweeteners, the commercialisation of SweetBiotix® meets a large global market need.
mol
FS, I was expecting /hoping for an update like you. Before calendar year end. But pretty unlikely now I suppose.
If SweetBiotix is a good product it needs to get to market. Competitors won't wait forever to launch alternatives. C'mon SOH !!
"We anticipate most results should be returned over the summer when we can start partner application development and launch plans."
I was wondering what people's thoughts were on the part of the summer Sweet RNS that I have copied above. I had thought that perhaps we would have an update by now given that the RNS referred to a process that was coming to an end in the summer. Is this the sort of thing that would require an RNS?
If only there were such a thing!
https://www.bbc.co.uk/news/business-67448897
Try the PBX board.
In light of this morning’s press comments that new NHS guidelines are advocating that over 2 million individuals are going to be told to boost their statin dose in order to slash cholesterol levels, shouldn’t more of an effort be made to promote the benefits of CholbiomeX3
Https://www.cambridgecommodities.com/home.htm
and scroll down
mol
Latest two news posts
https://www.cambridgecommodities.com/news/view,the-perfect-ingredient-for-gut-health-products_1024.htm
https://www.cambridgecommodities.com/news/view,change-the-way-you-take-your-vitamins-with-our-new-vegan-gummy-range_1022.htm
and whilst they have promoted us in the past neither of above, whilst both headlines could pertain to our products, has nowt to do with us - other than further evidence of ever increasing competition in the market in which we operate
12 years soon since formed and 10 years in July 24 since admission
mol
Mind presumably this is said Shiraz (along with a number of names, previously highlighted, giving reviews prior) of 5th Dec 23
https://www.amazon.co.uk/gp/customer-reviews/R1QFQSE3O8DC7H/ref=cm_cr_dp_d_rvw_ttl?ie=UTF8&ASIN=B0CDX99KCT
mol
Possibly the first noticeable improvement will be in our sales online website (and home website for that matter)
which, despite Stephen's robust defence of Shiraz, I continue to find amateurish
albeit online sales are increasing ( from a very low base) - but could be further and substantially improved imo with very little further spent on website with blogs etc updated on a regular basis and a minimal spend on advertising
mol
Frustrating it is DireCons
as to a bunch of chancers I can think of at least one uk plc listed on aim where that would appear to be the case though I hope I'm wrong - mind time is running out as 31 Dec rapidly approaching
mol
mol
To be fair to this Aussie website, if you try to find 'Patented Ingredient', Optislim don't list it as far as I can see.
They obviously need to list 'Slimbiome' as the patented ingredient.
Do we have a bunch of chancers running these outfits?
Frustrating.
Https://www.mealprep.com.au/p/choosing-a-meal-replacement-shake-that-works/
jees shouldn't be too difficult to put the undernoted right
Little information about their ‘patented’ ingredient
mol
I think he is referring to opti.gb.pl which as we know is for opti's shares traded on aquis market
but maybe not and the s is right beside the d - at least on my keyboard - lol
mol
Hopefully you can only see one set of shares now the drinks out of your system 😀
Can anyone tell me why Opti have 2 sets of shares listed on the market. Both prices are similar though why have 2 separate companies? Thanks in advance
Probably the best appointment
Stephen has made imo
I don't think we will have to wait too many months to guage his impact ( under 12 for sure)
I am now giving it towards end 2024 - mind what do I know - before selling up (all other things being equal)
bw all
mol
Oops meant to note there is no option for retired at companies house (from whence previous info is sourced) so it shows as resigned regardless of reason whereas presumably he retired from said appointments
mol
A useful summary on one page
https://suite.endole.co.uk/insight/people/6704094-mr-graham-lloyd-myers?page=companies
mol
A snippet from an interview from 2015 with Graham
https://www.youtube.com/watch?v=D56EKuzJm4c
I don't intend to become a subscriber to listen to the full 10 mins
mol
You’d need to be certifiable to trust Pfizer with what you of them since COVID.
Back to OPTI
https://is.gd/f3kyYU
We could do with this new appointee over at Sbtx. Are you listening Dr O'Hara.
Sometimes the answer is staring you in the face. All it needs is a basic non pharma solution, rather than the convoluted, mega expensive drug route? The costs have to be recouped and thus why pharma's are so rich.